Objective To systematically evaluate the efficacy and safety of Breviscapine Injection in the treatment of acute cerebral infarction（ACI）. Methods A total of eight electronic databases and clinical trials were searched to collect randomized controlled trials which were conducted on Breviscapine Injection in the treatment of ACI. According to the Cochrane Handbook 5. 1. 0 literature screening

data extraction and quality evaluation

the Chinese Stroke Clinical Neurological Deficit Rating Scale（CSS） and the National Institutes of Health Stroke Scale（NIHSS） were included in the final study. Meta-analysis of total efficacy

mortality

and neurological deficit scores

and the use of the GRADE system were used to grade the quality and grade recommendations for key outcome indicators. Results A total of 30 studies was included

and the methodological quality was generally low. Meta-analysis results showed the following facts. The combining use of Breviscapine Injection and conventional therapy was superior to conventional therapy in the total effective rate [RRCSS= 1. 28

95% CI =（1. 22

1. 34）

P < 0. 001;RRNIHSS=1. 16

95% CI =（1. 07

1. 25）

P < 0. 001]. In addition

Breviscapine Injection plus conventional therapy was statistically significant compared with venoruton plus conventional therapy in the total effective rate [RR = 1. 36

95%CI =（1. 26

1. 45）

P < 0. 001]. The mortality rate of breviscapine injection plus conventional therapy（14 days in acute phase） was lower than that of conventional therapy [RR = 0. 31

95% CI =（0. 10

0. 93）

P = 0. 04]. Based on GRADE

the level of evidence was low and the strength of recommendation was weak in total effective rate and mortality. The main adverse reactions of Breviscapine Injection were flush

slight dizziness that patients could endure and did not affect treatment. Conclusion Breviscapine Injection combined with conventional therapy has certain curative effects on acute cerebral infarction

lower the acute mortality rate and has less adverse reactions. Due to the low quality of the included study

more rigorous

high-quality

multi-centered

randomized double-blind controlled trials are required to increase the strength of the evidence in the future.